A review on immune checkpoint blockage therapy

S. Thamrook*,1, Shaiju S Dharan2, Merlin Nj3

1Mpharm, Ezhuthachan college of pharmaceutical sciences, Trivandrum, India.
2Department of pharmaceutical sciences, Ezhuthachan college of pharmaceutical sciences, Trivandrum, India.
3Department of pharmacology, Ezhuthachan college of pharmaceutical sciences, Trivandrum, India.

ABSTRACT

Activating the immune system to eliminate cancer cells and produce clinically relevant response has been a long standing goal of cancer research. Most promising therapeutic approaches of activating antitumor immunity include immune checkpoint inhibitors. Our immune system protect us from disease, killing bacteria and virus. One main type of immune cell called T-cells. T-cells have protein that turn it off. These are called checkpoint. Immune checkpoint are accessory molecules that either promote or inhibit T-cell activation. Checkpoint inhibitor are a type of immunotherapy. They block protein that stops the immune system from attacking the cancer cells. Checkpoint inhibitor are a type of monoclonal antibody or targeted treatment. Immune system cells, such as T-cells and Antigen presenting cells (APCs), defend and protect the body. Immune system play an important role in controlling and eradicating cancer. Cytotoxic T lymphocytes associated protein 4 (CTLA-4) and Programmed cell death protein (PD-1) are checkpoint protein which is the negative regulation of T-cell immune function. Inhibition of the target, results in increased activation of immune system.

Keywords: Checkpoint inhibitor; Immune therapy; T-cell; Monoclonal antibody.

ISSN: 2582-0672

Review Article

Corresponding Author

Name: Mr. S. Thamrook
Email: thamrushaji9423@gmail.com

Article Info

Received on: 24-11-2019
Revised on: 03-02-2019
Accepted on: 13-02-2019

DOI: https://doi.org/10.33974/ijrhcp.v2i1.159

Fundamental mechanism of immune checkpoint blockade therapy

Immune checkpoint blockade removes inhibitory signals of T-cell activation, which enables tumour-reactive T cells to overcome regulatory mechanism and form an effective antitumor response. Immune checkpoint blockade therapies are now FDA approved for the treatment of a broad range of tumor type with approval likely for additional indications in
the future. Since the 2011 FDA approval of ipilimumab (anti-CTLA4) for the treatment of metastatic melanoma, 5 additional checkpoint blockade therapies, all targeting the PD-1/PD-L1 axis, have been approved for the treatment of a broad range of tumor types. Additionally, ipilimumab plus nivolumab (anti-PD-1) combination therapy has been approved for the treatment of advanced melanoma. The mechanism of checkpoint blockade is to be understood[6].

Five types of mechanism involved are;

1. Mechanisms of CTLA4-mediated negative costimulation.
2. Mechanism of PD-1-mediated attenuation of T-cell activity.
3. Mechanism of negative costimulation versus mechanisms of checkpoint blockade.
4. Mechanism of action of CTLA4 blockade-induced tumor rejection.
5. Mechanism of action of PD-1 blockade-induced tumor rejection.

![Figure 1: Molecular mechanisms of CTLA4 and PD-1 attenuation of T-cell activation.](image1)

Mechanism of cta4-mediated negative costimulation

CTLA4 expression and function is basically linked with T-cell activation. CTLA4 is immediately upregulated following T-cell receptor (TCR) commitment (signal 1), with its expression peaking 2 to 3 days after activation. CTLA4 dampens TCR signaling through competition with the costimulatory molecule CD28 for the B7 ligands B7-1(CD80) and B7-2(CD86), for which CTLA4 has higher avidity and affinity (Figure :1). Because of both B7-1 and B7-2 provide positive costimulatory signals through CD28, competitive inhibition of both molecules by CTLA4 is necessary to useful. It satisfy T-cells activation. In addition to upregulation of CTLA4 expression upon T-cell activation, CTLA4 contained in intracellular vesicles is rapidly trafficked to the immunologic synapse[3]. The degree of recruitment to the immunologic synapse correlates directly with TCR signal strength. Through this mechanism, CTLA4 attenuates positive costimulation by CD28 and thus limits CD28 downstream signaling, which is primarily mediated PI3K and AKT[4]. This fallout in robust regulation of TCR signal amplitude and thus, T-cell activity. Because CTLA4 negative costimulation is intrinsically linked to expression of B7 ligands and CD28-mediated positive costimulation, CTLA4 primarily functions to regulate T-cell activity at site of T-cell priming (eg; secondary lymphoid organs). In addition to this core function, CTLA4 also attenuates T-cell activation in peripheral tissues given that B7 ligands are constitutively expressed to varying degrees by antigen-presenting cells (APC) but can also expressed by activated T cells[5]. Because of its vital role in regulating T-cell activation, negative costimulation by CTLA4 is critical for tolerance. The majority of cell-extrinsic suppressive function of CTLA4 is mediated through Regulatory T cells (Tregs). The genetic loss of CTLA4 in Tregs in middle age. A significant implication of this finding is that Treg depletion may counter expansion of Treg cells induced by CTLA4 blockade and thus lead to enhanced efficacy of anti-CTLA4 therapy[6].

![Figure 2: Schematic of the molecular mechanisms of action of CTLA4 and PD blockade](image2)

**Table 1: List of FDA approved immune checkpoint blockade therapy**

| Tumor type                          | Therapeutic agent               |
|-------------------------------------|---------------------------------|
| Melanoma                            | Ipilimumab                      |
| Melanoma                            | Nivolumab                       |
| Melanoma (BRAF wild-type)           | Ipilimumab, nivolumab           |
| Melanoma (adjuvant)                 | Ipilimumab                      |
| Renal cell carcinoma                | Nivolumab                       |
| Hodgkin lymphoma                    | Nivolumab                       |
| Urothelial carcinoma                | Atezolizumab                    |
| Head and neck squamous cell carcina | Nivolumab                       |
| Head and neck squamous cell carcina  | Pembrolizumab                  |
| Melanoma (any BRAF status)          | Ipilimumab, nivolumab           |
| Non–small cell lung cancer          | Atezolizumab                    |
| Hodgkin lymphoma                    | Pembrolizumab                   |
| Merkel cell carcinoma               | Avelumab                        |
| Urothelial carcinoma                | Avelumab                        |
| Urothelial carcinoma                | Durvalumab                      |
| Urothelial carcinoma                | Nivolumab                       |
Mechanism of pd-1 mediated attenuation of t-cell activity

The key biological functions of PD-1 are to maintain peripheral tolerance and to maintain T-cell response within a desired physiologic range. Because the PD-1/PD-L1 regulatory system is induced by immune responses, this forms a negative feedback loop to attenuate local T-cell response and reduce tissue damage[7]. PD-L1 regulates T-cell activation through interaction with PD-1 and PD-L2 (Figure:2). PD-1 is expressed upon activation of T and B lymphocytes. PD-1 acts primarily to reduce T-cell activation in the periphery. Upon meeting with PD-L1 and PD-L2, PD-1 is through to primarily convey a negative costimulatory signal through the tyrosine phosphatase SHP2 to attenuate T-cell activation. The molecular mechanism reflects a dichotomy in modes of regulation utilized by CTLA4 and PD-1 engagement[8,9]. These data indicate that in contrast to CTLA4 mediated regulation, PD-1 directly regulates TCR signaling to attenuate T-cell activity. Recently indicates that CD28 is a primary target for PD-1 induced attenuation of T-cell signaling. PD-1 is essential for homeostatic maintenance of peripheral tolerance as evidenced by the autoimmune pathologies that arise upon genetic deletion of pdcdl (encoding PD-1). As an example genetic loss of pdcdl leads to development of lupus like autoimmune pathology in aged mice and autoimmune dilated cardiomyopathy in mice[10].

Mechanism of negative costimulation versus mechanisms of checkpoint blockade

Based on study of how the molecule themselves act to attenuate T-cell activity, it is thought that anti-CTLA4 and anti-PD-1 primarily act at different stages of the cancer-immunity cycle. Obstruction of PD-1 is sufficient to improve the activity of exhausted T cells in the context of chronic viral infection, leading to viral clearance. Recent finding demonstrate that CD28 costimulation is necessary for response to PD-1 blockade in the setting of both viral infection and tumor rejection[11,12]. These finding indicates that additional positive costimulation is required for therapeutic efficacy despite prior activation. Mechanism of action of PD-1 and CTLA4 blockade and of the normal biological functions of these molecules are highly complex and clearly not fully understood [13].

Mechanism of action of ctlA4 blockade-induced tumor rejection

CTLA4 blockade is thought to encourage tumor rejection through a number of distinct mechanisms. The primary mechanism seems to be through direct blockade of CTLA4 competition of B7-1 and B7-2 costimulatory ligands, which allows for unrestrained CD-28 mediated positive costimulation[14]. CTLA4 complex disclose that the ipilimumab binding epitope overlaps with the B7 interaction domain, indicating that steric inhibition of B7 interaction underlies the primary mechanism of action of ipilimumab. It is also possible that APCs within the the tumor microenvironment may also cross present tumor antigens to activate cognate tumor-associated antigens[15]. Promising evidence suggest that anti-CTLA4 does not impose a generalized effect on all T cells. CTLA4 blockade leads to specific expansion of tumor neoantigen-specific CD8 T cells within the tumor microenvironment, but secondary lymphoid organs[16]. In addition to these mechanism of CTLA4 blockade-induced tumor rejection, reduction of Treg population has also been identified as a mechanism of action of anti-CTLA4 therapy in murine tumor models. Although other prior studies do suggest that Treg depletion contributes to the mechanism of action of anti-CTLA4, a large body of work powerfully implicates regulation of B7 ligand interaction as a critical mechanism[17].

Mechanism of action of pd-1 blockade-induced tumor rejection

PD-1 blockade is capable to induce tumor rejection through energy of CD8 T cells, leading to both increased functional activity and frequency. Blockade of the PD-1 signaling axis avoid PD-1 mediated attenuation of proximal TCR signaling, allowing for restoration of activity of exhausted CD8 effectors[18,19]. Current evidence from a neoadjuvant trial of nivolumab in the context of non-small cell lung cancer support the motion that anti-PD-1 therapy develop neoantigen-specific T cell response. It is probable that only specific T-cell populations functionally mediate response to checkpoint blockade therapy[20]. These data suggest that PD-1 blockade may not be enough to functionally restore T cells once they reach a threshold level of exhaustion. It remains unclear what specific aspects of CD4 help are functionally necessary for clinical response to checkpoint blockade[21].

Mechanisms of resistance to immune checkpoint inhibitor

Monoclonal antibodies targeting co-inhibitory immune checkpoints (eg: PD-1 and CTLA 4) have demonstrated clinical activity in several malignancies, including melanoma, non-small cell lung cancer, renal cell carcinoma and bladder cancer. Immune checkpoint inhibitor therapy has been particularly successful in melanoma, for which approved treatments now include anti-PD-1 (nivolumab and pembrolizumab), anti-CTLA4 (ipilimumab), and combination anti-PD-1/CTLA-4 regimens (nivolumab-ipilimumab). Long-term survival data for patients with melanoma treated with ipilimumab (anti-CTLA4) indicates 20% of patients show evidence of continued durable disease control or response 5-10 years after starting therapy. The response rate for melanoma patient treated with pembrolizumab (anti-PD-1) was 33% at 3years with
70-80% of patient initially responding maintaining clinical response(Figure; 3). Combination immunotherapy or dual immune checkpoint blockade (anti-PD-1 and anti-CTLA-4) has recently shown spectacular response rates in patients with metastatic melanoma[9].

Analysis of clinical trial data can identify three populations of patient

1. Peoples that respond initially and continue to respond (responder).
2. Peoples that fail to ever respond (innate resistance).
3. Peoples that initially respond but eventually develop disease progression (acquired resistance).

Figure 3: Schematic representation of mechanism of resistance to immune checkpoint inhibitor

Mechanism of innate and acquired resistance to ICI (Immune checkpoint inhibitor) therapy are not fully understood. In addition, few immune competent preclinical models exist in which tumor regression is induced by ICIs, limiting the ability to recapitulate the diversity of tumor-immune interactions in patients[22]

3 simple categories

1. Inadequate generation of anti tumor T cells
2. Insufficient function of tumour-specific T cells
3. Impaired formation of T-cell memory

Inadequate generation of anti-tumour t-cell

Tumors can evolve to evade both innate and adaptive arms of the immune system there by rendering ICI therapy ineffective[23,24]. Tumor intrinsic mechanisms of immune evasion include genetic and epigenetic alterations to influence neoantigen formation, presentation, and/or processing, as well as alterations in cellular signalling pathways that disrupt the action of cytotoxic T cells. Tumor extrinsic mechanisms involve non-cancerous stromal or immune cells, or other systemic influences (e.g., host microbiota) that can act in concert with cancer cells to uphold growth and resistance to ICI[25].

Insufficient function of tumor specific cell

Successful neoantigen presentation/cross-presentation and T-cell priming, the expanded repertoire of anti-tumour T cells faces an inhospitable TME that may preclude proper T-cell function, thereby limiting the efficacy of ICI therapy[26]. These tumour intrinsic and tumour-extrinsic factors include mutations in key effector pathways, high levels of PD-L1 on tumour cells (and immune cells), high levels of alternate immune checkpoints or co-inhibitory receptors on T cells (e.g;PD-1, CTLA-4), high levels of immune suppressive cytokines or metabolites, and associated recruitment of immune suppressive cells (e.g;myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs)[27].

Impaired formation of t-cell memory

The most compelling clinical evidence for the success of ICI relates to the potential for long-term, durable clinical profit. Thus, although ICI may temporarily strengthen CTLs to enhance tumour control, if formation of T_{EM} cells is impaired then clinical response could fade leading to acquired resistance or recurrence of disease following discontinuation of therapy. Expansion of intratumoral T_{EM} in response to PD-1 blockade has been demonstrated, and is more pronounced in patients responding to therapy, suggesting a key role for T_{EM} cells in anti-PD-1 action and clinical response. The cellular and molecular mechanisms of T_{EM} expansion following PD-1 blockade are not fully understood[28,29].

CONCLUSION

Immune checkpoint therapy, which target regulatory pathways in T cells to enhance antitumor immune responses, has lead to important clinical advances and provide a new weapons against cancer. This therapy has elicited clinical responses and, in a fraction of patient, long term remissions where patient exhibit no clinical signs of cancer for many years. The way forward for this class of novel agents lies in our ability to understand human immune responses in tumor microenvironment. This will provide valuable information regarding the dynamic nature of immune responses and regulate additional pathways that will need to be targeted through combination therapies to provide survival benefits for greater numbers of patients.

REFERENCES

1. Keji Sugiuari, Mariko Sugiura. Immune checkpoint blockade therapy merits and demerits. Journal of clinical and Experimental Dermatology research. 2016;7: 1-3.
2. Spencer C. Wei, Colm R. Duffy, James P.Allison. Fundamental mechanism of immune checkpoint blockade therapy. American association for cancer research. 2018;18:1069-1081.

3. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1:405-13.

4. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol 1999;162:5813-20.

5. Egen JG, Allison JP. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 2002;16:23-35.

6. Pentcheva-Hoang T, Egen JG, Wojnoonski K, Allison JP. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 2004;21:401-13.

7. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996;8:765-72.

8. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 2006;203:883-95.

9. Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, HashimotoTane A, Azuma M, Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med 2012;209:1201-17.

10. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005;25:9543-53.

11. Chen DS, Mellman I. Oncology meets immunology: the cancer immunology cycle. Immunity 2013;39:1-10.

12. Wherry EJ. T cell exhaustion. Nat Immunol 2011;12:492-9. 53. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439:682-7.

13. Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science 2017;355:1423-7.

14. Ramagopal UA, Liu W, Garrett-Thomson SC, Bonanno JB, Yan Q, Srinivasan M, et al. Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab. Proc Natl Acad Sci U S A 2017;114:E4223-32.

15. Dieu-Nosjean MC, Antoine M, Daniel C, Heudes D, Wislez M, Poulot V, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008;26:4410-7.

16. Engelhard VH, Rodriguez AB, Mauldin IS, Woods AN, Peske JD, Slingluff CL Jr. Immune cell infiltration and tertiary lymphoid structures as determinants of antitumor immunity. J Immunol 2018;200:432-42.

17. Joshi NS, Akama-Garren EH, Lu Y, Lee DY, Chang GP, Li A, et al. Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses. Immunity 2015;43:579-90.

18. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-7.

19. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71.

20. Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 2016;537:417-21.

21. Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 2017;545:60-5.

22. Russell W Jenkins, David A Barbie, Keith T Flaherty. Mechanisms of resistance to immune checkpoint inhibitors. British journal of cancer. 2018;118(1): 9-16.

23. Gajewski TF, Schreiber H, Fu XY (2013) Innate and adaptive immune cells in the tumour microenvironment. Nat Immunol 2013;14:1014-1022.

24. Pitt JM, Vetizou M, Daillere R, Roberti MP, Yamazaki T, Routy B, Lepage P, Boneca IG, Chamaillard M, Kroemer G, Zitvogel L. Resistance mechanisms to immune checkpoint blockade in cancer: tumour-intrinsic and -extrinsic factors. Immunity 2016;44:1255-1269.

25. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014;515:577-581.

26. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, HuLieskovski S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Socco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 2016;375:819-829.

27. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C. Fc-dependent
depletion of tumour-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013;210:1695-1710.

28. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Association of pembrolizumab with tumour response and survival among patients with advanced melanoma. JAMA 2016;315:1600-1609.

29. O’Donnell JS, Long GV, Scolyer RA, Teng MW, Smyth MJ, Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev 2017;52: 71-81.